76 related articles for article (PubMed ID: 21326154)
1. Abiraterone in prostate cancer.
Ryan C
Clin Adv Hematol Oncol; 2010 Nov; 8(11):761-2. PubMed ID: 21326154
[No Abstract] [Full Text] [Related]
2. Abiraterone: current and future use in prostate cancer.
Ryan CJ
Clin Adv Hematol Oncol; 2012 Mar; 10(3):180-1. PubMed ID: 22402426
[No Abstract] [Full Text] [Related]
3. Use of abiraterone for prostate cancer.
Mohler JL; Pantuck AJ
J Urol; 2011 Mar; 185(3):783-6. PubMed ID: 21239011
[No Abstract] [Full Text] [Related]
4. Abiraterone. Cougar Biotechnology.
Madan RA; Arlen PM
IDrugs; 2006 Jan; 9(1):49-55. PubMed ID: 16374734
[TBL] [Abstract][Full Text] [Related]
5. NICE recommends abiraterone for prostate cancer after manufacturer reduces price.
Kmietowicz Z
BMJ; 2012 May; 344():e3520. PubMed ID: 22611169
[No Abstract] [Full Text] [Related]
6. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Prescrire Int; 2012 Jun; 21(128):147-9. PubMed ID: 22822591
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: moving forward by reinventing the wheel...but this time it is round.
Raghavan D; Klein EA
J Clin Oncol; 2008 Oct; 26(28):4535-6. PubMed ID: 18626003
[No Abstract] [Full Text] [Related]
8. Cancer expert doubts claims about prostate cancer trial.
Cole A
BMJ; 2008 Jul; 337():a979. PubMed ID: 18653636
[No Abstract] [Full Text] [Related]
9. Prostate cancer: score one for validated targets.
Bates SE
Clin Cancer Res; 2011 Jun; 17(12):3866. PubMed ID: 21680541
[No Abstract] [Full Text] [Related]
10. Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
Prescrire Int; 2014 Feb; 23(146):40-1. PubMed ID: 24669383
[TBL] [Abstract][Full Text] [Related]
11. FDA approves prostate cancer treatment that inhibits testosterone synthesis.
Thompson CA
Am J Health Syst Pharm; 2011 Jun; 68(11):960. PubMed ID: 21593221
[No Abstract] [Full Text] [Related]
12. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.
Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
Br J Cancer; 2014 Jan; 110(1):267-8. PubMed ID: 24300975
[No Abstract] [Full Text] [Related]
13. Comment on 'Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.
Shamash J; Sarker SJ
Br J Cancer; 2014 Jan; 110(1):266-7. PubMed ID: 24300970
[No Abstract] [Full Text] [Related]
14. Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.
Pia A; Vignani F; Attard G; Tucci M; Bironzo P; Scagliotti G; Arlt W; Terzolo M; Berruti A
Cancer Treat Rev; 2013 Dec; 39(8):966-73. PubMed ID: 23582279
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate.
Logothetis CJ; Efstathiou E; Manuguid F; Kirkpatrick P
Nat Rev Drug Discov; 2011 Aug; 10(8):573-4. PubMed ID: 21804589
[No Abstract] [Full Text] [Related]
16. Role of androgens in abiraterone resistance.
Colloca G
J Clin Oncol; 2012 Oct; 30(28):3561-2: author reply 3562. PubMed ID: 22915660
[No Abstract] [Full Text] [Related]
17. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer hope.
Wallis L
Nurs Stand; 2008 Oct 8-14; 23(5):21. PubMed ID: 18947077
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone and MVD3100 take androgen deprivation to a new level.
Schmidt C
J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
[No Abstract] [Full Text] [Related]
20. New prostate cancer drug: Prostate cancer's day in the sun.
Attard G; Reid AH; Dearnaley D; De Bono JS
BMJ; 2008 Aug; 337():a1249. PubMed ID: 18694888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
